For those that have already done this, or are in the middle of mitigating this:

We appear to have some buy-in with oxytocin regarding the ISMP best practice, but we have not seen movement on the last portion of the recommendation in the actual data. It reads, "avoid bringing oxytocin infusion bags to the patient's bedside until it is prescribed and needed."

What have you found that can help change hearts and minds in this arena? Are there posters or something that someone can point to that would help?

Does your health system or hospital have a pharmacy-driven vaccination protocol for inpatients (influenza and pneumococcal)? Have you experienced any barriers? Would you be willing to share your protocol?

I am new to an institution that uses Cerner and trying to understand its build in relation to a problem I hope you can help me with.

For those that use Cerner do you have issues with viewing trade and generic names together?
We have several medications where if the trade name is ordered it does not display with the generic name.
This led to a patient having the same med ordered twice, one as the trade and one as the generic and received several doses before this was picked up.

In trying to solve the issue I was told it has to do with building the IV set

Wondering if anyone knows why Aminoglycosides are not on the NIOSH list since they are known to cause ototoxicity to the unborn fetuses?

what does your hospital do when administering amikacin/tobramycin as a nebulization?
Do the parents/guardians leave the room? what happens to the next patient/family in the next bed?

We are an Epic health system and recently implemented a best practice advisory prompting an oncology consult when a provider tried to continue a home oral chemotherapy during admission med reconciliation. We still have instances where the oral agent was continued without the consult or was continued upon discharge with discharge med rec. Has anyone blocked ordering to just oncology or have a different solution that has worked at your location?

We are going to the gemba to understand our workflows of med admin through observation. If there is a system that is willing to share a med admin observation tool they have used, please attach. Thank you in advance!

Terry Bosen, PharmD
Vanderbilt University Medical Center
Nashville, TN

Good morning,

We use Cerner and are trying to restrict MAR documentation of respiratory therapist to just inhaled routes for medications that can also be given using other routes (i.e., acetylcysteine, tobramycin, etc). This is a concern because of the risk of incorrectly documenting on IV orders.

Has anyone been successful in restricting MAR documentation for respiratory therapists to just inhaled and nebulized routes?

Thank you,
Julieth Formosa

It appears that some states are opening up Class J licenses for Pharmacies to participate in shared services (covering clinical, operational, and/or other medication management functions for another pharmacy campus).

One requirement is to have a QA process. Which other health-systems are pursuing this level of license? How do you have your QA process set-up? Which metrics have you considered?

Thank you in advance,
Joel

#

Hi everyone,

We are interested to see if any institutions have experience with outpatient clinics that might see a mixed age group (adults and pediatrics)?

And if so, what are some best practices used at your institution to store medications?

Thank you!
Susan

Greetings,
Our institution has anecdotally noticed an uptick in iron sucrose adverse drug reactions. Is this occurring anywhere else? Our infusion center uses the branded Venofer product.

Sloane Hoefer, PharmD, BCPS
Nebraska Medicine